Efdoralprin alfa

SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT"), augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency. On May 30, 2024, the Former Parent completed the transaction, pursuant to which (i) all assets and liabilities primarily related to INBRX-101 (the "101 Business"), were transferred to Aventis Inc. (the "Acquirer"), a wholly-owned subsidiary of Sanofi S.A. ("Sanofi"); and (ii) by way of a pre-closing reorganization (the "Separation"), the Company acquired the assets and liabilities and corporate infrastructure associated with its ongoing programs, INBRX-106 and ozekibart (INBRX-109), and its discovery pipeline, as well as the remaining close-out obligations related to its previously terminated program, INBRX-105. Upon the closing, each Former Parent stockholder received: (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx Biosciences for every four shares of the Former Parent's common stock held. The Former Parent retained an equity interest in Inhibrx Biosciences of 8% upon the distribution of shares to the Former Parent stockholders (the "Distribution"). In connection with the Separation, the Acquirer paid transaction consideration totaling approximately $2.2 billion in aggregate value, including the $35.00 per share consideration and the assumption of the third-party debt obligations of the Former Parent. In addition, the Acquirer assumed all assets and liabilities under contracts primarily related to INBRX-101 upon close of the transaction. The Acquirer also reimbursed the Company or paid on behalf of the Company $68.0 million in transaction costs. From and after the closing, Inhibrx Biosciences continues to operate as a stand-alone, publicly traded company focused on its two clinical programs, ozekibart (INBRX-109) and INBRX-106. Inhibrx Biosciences continues to trade as INBX on the Nasdaq Global Market. We do not expect the results of operations directly arising from and related to the Separation and Distribution to occur in future periods. Financial Results Cash and Cash Equivalents. As of June 30, 2024, Inhibrx Biosciences had cash and cash equivalents of $226.9 million, compared to $255.4 million as of May 30, 2024 following the Separation from the Former Parent. The Company's cash outflows during this period relate primarily to the distribution of consideration totaling $17.7 million, which was paid out to the Former Parent's optionholders and remitted by the Company within ten business days of the close of the transaction in accordance with the terms of the Separation and Distribution. Other cash outflows during the period relate to the Company's ongoing operations. R&D Expense. Research and development expenses were $67.6 million during the second quarter of 2024, compared to $34.1 million during the second quarter of 2023. The increase in research and development expenses was primarily due to the following factors: stock option expense recognized upon the acceleration of outstanding stock options in connection with the Separation and Distribution; an increase in CMC expenses due to the nature of the development and manufacturing activities performed at its CDMO and CRO partners supporting the Company's clinical and preclinical therapeutic candidates, which reflect the stage-specific needs of its programs during each period, including early and late-stage drug substance clinical manufacturing, analytical development, quality control, testing and stability studies, drug product development, scale-up, robustness studies, and selected biologics license applications-enabling activities; and offset in part by a decrease in clinical trial expenses following the termination of the Company's INBRX-105 program and the removal of the INBRX-101 program following the Separation. G&A Expense. General and administrative expenses were $93.4 million during the second quarter of 2024, compared to $7.3 million during the second quarter of 2023. The increase in general and administrative expenses was primarily due to the following factors: an increase in legal, advisory, and consulting fees incurred in connection with the Separation and Distribution; stock option expense recognized upon the acceleration of outstanding stock options in connection with the Separation and Distribution; an increase in pre-commercialization expenses, which was primarily related to increases in consulting services to support the Company's commercial operations business intelligence strategies and market research expenses related to ozekibart (INBRX-109) and INBRX-101 prior to the transaction; an increase in professional service expenses related to legal services which support the Company in its general corporate and intellectual property matters, and legal proceedings. Other Income (Expense). Other income was $2.0 billion during the second quarter of 2024, compared to other expense of $5.7 million during the second quarter of 2023. Other income during the second quarter of 2024 consists of gains recorded in connection with the completion of the Separation and Distribution, related to (i) the consideration paid by the Acquirer for all outstanding common stock, warrants, and stock options, (ii) the extinguishment of the Company's outstanding debt which was assumed by the Acquirer, (iii) assets and liabilities related to the 101 Business, which were assumed by the Acquirer, and (iv) transaction costs paid for by the Acquirer. Net Income (Loss). Net income was $1.9 billion during the second quarter of 2024, or earnings per share of $127.10, basic, and $125.48, diluted, compared to a net loss of $47.1 million during the second quarter of 2023, or $4.31 per share, basic and diluted. About Inhibrx Biosciences, Inc. Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. For more information, please visit . Forward Looking Statements Inhibrx Biosciences cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx Biosciences' current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx Biosciences' and its investigators' judgments and beliefs regarding the strength of Inhibrx Biosciences' pipeline and the observed safety and efficacy to date of its therapeutic candidates; whether a trial is registration-enabling; future clinical development of Inhibrx Biosciences' therapeutic candidates, including any potential for approval or accelerated approval or implication that the results of earlier clinical trials or studies will be representative of later clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx Biosciences' business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of preclinical data and initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals, including whether any product candidate receives approval from the United States Food and Drug Administration, or similar regulatory authority, for an accelerated approval process; the commercialization of the Company's therapeutic candidates, if approved; the pricing, coverage and reimbursement of the Company's therapeutic candidates, if approved; the Company's ability to utilize the Company's technology platform to generate and advance additional therapeutic candidates; the implementation of the Company's business model and strategic plans for the Company's business and therapeutic candidates; the Company's ability to successfully manufacture the Company's therapeutic candidates for clinical trials and commercial use, if approved; the Company's ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection the Company is able to establish and maintain for intellectual property rights covering the Company's therapeutic candidates; the Company's ability to enter into strategic partnerships and the potential benefits of such partnerships; the Company's estimates regarding expenses, capital requirements and needs for additional financing; the ability to raise funds needed to satisfy the Company's capital requirements, which may depend on financial, economic and market conditions and other factors, over which the Company may have no or limited control; the Company's financial performance; the Company's and the Company's third party partners' and service providers' ability to continue operations and advance the Company's therapeutic candidates through clinical trials and the ability of the Company's third party manufacturers to provide the required raw materials, antibodies and other biologics for the Company's preclinical research and clinical trials in light of current market conditions or any pandemics, regional conflicts, sanctions, labor conditions, geopolitical events, natural disasters or extreme weather events; the ability to retain the continued service of the Company's key professionals and to identify, hire and retain additional qualified professionals; and developments relating to the Company's competitors and the Company's industry; and other risks described from time to time in the "Risk Factors" section of its filings with the U.S. Securities and Exchange Commission, including those described in its Registration Statement on Form 10, as amended (File No. 001-42031) as well as its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K as filed from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx Biosciences undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor and Media Contact: Kelly D. Deck Chief Financial Officer [email protected] 858-795-4260 SOURCE Inhibrx Biosciences, Inc.

全球免疫学市场预计到2032年将翻近一番，达到2500亿美元。以下是今年该领域的杰出交易。 2023年初生物科技投资经历了一段艰难时期后，默克公司以108亿美元收购了普罗米修斯生物科学公司，为行业注入了活力。总体而言，根据生物技术企业家Andrew Pannu的数据，去年治疗性免疫学和炎症（I&I）领域共发生了123亿美元的并购活动。 Taylor Tieden for BioSpace “免疫学和炎症一直是制药公司的特别关注领域……主要由这样一个想法推动，即……免疫疾病和炎症状况很多时候具有共同的作用机制，”Mizuho Americas的高级生物制药和生物技术股票研究分析师Graig Suvannavejh说。“任何被证明是安全有效的药物，并获得多个疾病或多个适应症的批准……那是持续给予的礼物。” 事实上，全球免疫学市场预计将从2024年的约1032亿美元增长到2032年的2574亿美元。 除了庞大的患者群体（十分之一的人至少患有一种免疫疾病），报销是I&I投资活动的一个激励因素，根据Janus Henderson Investors的报告。报告中说：“许多自身免疫疾病患者是儿童或工作年龄的人，因此他们长时间停留在治疗上。此外，在美国，这些患者通常属于商业保险计划，不受现在允许在Medicare（政府为老年人提供的保险计划）中进行药品价格谈判的限制。” 而且，不仅仅是传统的I&I疾病如类风湿关节炎、牛皮癣、1型糖尿病、多发性硬化症和克罗恩病受到关注。被假设具有神经炎症原因的神经退行性疾病，如阿尔茨海默病和帕金森病，也在逐渐进入这个领域。 “这里有一种复兴，神经学、神经退行性疾病[和]精神病学领域又变得时髦起来，”Suvannavejh说。他说，许多大型制药公司在1990年代末和2000年代初在神经科学领域拥有巨大的特许经营权，但许多由此产生的药物都成为了通用名药物，对该领域的关注也减少了。他说，当前的复苏是由于多种因素，例如专利悬崖以及公共和私营部门在科学和创新方面取得的巨大进步。 以下是今年的杰出I&I交易： 传统I&I交易Vertex-Alpine 4月，49亿美元 Alpine的主要资产povetacicept是BAFF和APRIL细胞因子的双重拮抗剂，这两者在B细胞的激活、分化和存活中都发挥着关键作用。Povetacicept正在被研究用于治疗IgAN，这是一种影响肾脏并最终导致终末期肾病的进行性自身免疫疾病。 Eli Lilly-Morphic 7月，32亿美元 Morphic正在研究一类名为整合素的蛋白质，它们运输T细胞。“有这样一种想法，整合素对于你的T细胞到达炎症区域的能力很重要，”Suvannavejh说。 Morphic的主要候选药物MORF-057是一种小分子α4β7整合素抑制剂。目前正在开发用于治疗溃疡性结肠炎和克罗恩病，这两种都是炎症性肠病。 Biogen-HI-Bio 6月，18亿美元 为了降低其投资组合的风险，Biogen收购了HI-Bio，以获取其资产felzartamab。该候选药物选择性耗尽CD38+细胞的机制可能会赋予Biogen“适用于一系列免疫介导疾病的范围”，蒙特利尔资本市场分析师在5月给投资者的一份报告中表示。 BMS-Repertoire 4月，18亿美元 百时美施贵宝最近与Repertoire达成了一项为期3年的协议，为多达三种自身免疫疾病创建耐受性疫苗，尽管有关正在针对哪些疾病的详细信息尚未公布。 “我们与Repertoire的合作旨在选择性地重置免疫系统，这反映了我们免疫学研究战略的关键组成部分，我们认为这可能提供长期的好处，同时减轻与广泛免疫抑制相关的意外后果，”BMS免疫学与心血管主题研究中心主任Francisco Ramírez-Valle在一份声明中说。 AbbVie-OSE 2月，7.13亿美元 代表I&I“旗舰”药物Humira和流行的Skyrizi，AbbVie收购了OSE Therapeutics的早期单克隆抗体OSE-230，作为治疗慢性和严重炎症的药物。这种抗体通过靶向和激活ChemR23发挥作用，ChemR23是一种G蛋白偶联受体，在某些有助于抑制炎症的信号通路中起着核心作用。 Humira去年失去了专利保护，面临生物仿制药的竞争，因此AbbVie正在寻求通过新交易弥补专利悬崖造成的损失。“他们在Humira上有着传统的存在，所以他们已经建立了商业基础设施，”Suvannavejh说。“他们知道如何在免疫疾病和炎症疾病中销售这些药物。” Sanofi-Belharra 6月，7亿美元 这次合作将利用Belharra的非共价化学蛋白质组学平台，识别并推进针对Sanofi指定的未公开免疫学靶点的小分子。“通过利用Belharra的化学蛋白质组学平台，我们希望能够探索迄今为止被认为无法成药的免疫学靶点，”Sanofi全球免疫学和炎症研究负责人John Bertin在一份声明中说。 AbbVie-Landos 3月，2.12亿美元 Landos的主要资产NX-13是一种用于溃疡性结肠炎和克罗恩病的口服NLRX1激动剂。其作用机制是抗炎并促进上皮修复，这是溃疡性结肠炎和克罗恩病中受损的自然功能。Landos的创始人认为，这笔交易“反映了市场已经准备好接受新选择，特别是采用新作用机制的药物。” Sanofi-Inhibrx 1月，22亿美元 Inhibrx的主要资产INBRX-101针对的是α1抗胰蛋白酶缺乏症（AATD），这是一种罕见疾病，使患者面临肺部、肝脏或皮肤疾病的风险。根据Inhibrx的说法，INBRX-101以比目前可用药物更少的剂量使患者的血清AAT水平正常化。 Suvannavejh说，这笔交易解决了一个缺乏的问题，而不是由免疫系统过度活跃引起的疾病，因此他认为它与I&I属于不同的类别。但Sanofi的研发负责人Houman Ashrafian在一份声明中表示，这次收购是公司努力扩大在免疫介导的呼吸状况中的存在的一部分。声明指出，该药物可能有助于减少炎症并防止肺功能恶化。 参考资料：https://www.biospace.com/deals/top-i-i-deals-so-far-in-2024 识别微信二维码，添加生物制品圈小编，符合条件者即可加入 生物制品微信群！ 请注明：姓名+研究方向！ 版 权 声 明 本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。